# Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation

> **NCT01491958** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** atorvastatin
- **DRUG:** Tacrolimus
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT01491958
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-10
- **Primary completion:** 2014-01-01
- **Final completion:** 2016-06-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491958, "Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01491958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*